NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Grifols, S.A. (GRFS) Stock Analysis

Grifols, S.A. (GRFS) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

GRFS

$7.80

−$0.08 (−1.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GRFS with… →

GRFS Key Statistics

As of Sep 4, 2026
Trading
Open
$7.82
Previous Close
$7.88
Day's Range
7.77–7.84
52-Week Range
6.96–10.23
Volume
157.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.19
Valuation
Market Cap
$5.31B
P/E Ratio
10.26
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.41
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.19
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.72
EPS (ttm)Profit attributable to each share over the last twelve months.
0.76
Financials (FY)
Revenue (FY)
$7.52B+4.33%
Net Income (FY)
$402.00M+156.05%
Profit marginThe share of revenue left as profit after all costs and taxes.
6.09%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
258.22M
1-Year Return
−20.15%
Dividend and dates
Dividend
$0.28+3.58%
Ex-Dividend Date
July 2, 2026
Avg Volume
628.23K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GRFS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−15.46%
2025+27.76%
2024−35.64%
2023+36.00%
2022−24.31%
2021−37.47%
2020−19.87%
2019+29.29%
2018−18.07%
2017+45.07%
2016 (partial year)−1.84%

As of September 4, 2026.

GRFS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.52B$402.00M5.3%
2024$7.21B$157.00M2.2%
2023$6.59B$42.00M0.6%
2022$6.06B$185.04M3.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.52B$2.86B$1.25B$402.00M5.3%
2024$7.21B$2.79B$1.16B$157.00M2.2%
2023$6.59B$2.48B$718.00M$42.00M0.6%
2022$6.06B$2.21B$678.96M$185.04M3.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GRFS Dividend History

$0.17

Dividends per share, 2025 · 1 payments

YearDividends per sharePaymentsChange
2026*$0.091—
2025$0.171—
2021$0.461+126.9%
2020$0.201−49.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.091—
2025$0.171—
2021$0.461+126.9%
2020$0.201−49.0%
2019$0.392−17.7%
2018$0.482+27.7%
2017$0.382+96.3%
2016$0.191—

Most recent payment: $0.09 per share, ex-dividend July 2, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

GRFS Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricGRFSDrug Manufacturers - General medianvs median
P/E10.2624.6958% below
P/S ratio0.723.130.2x the median
Profit margin6.09%8.09%2.0 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Grifols, S.A. (GRFS) is capitalised at $5.31B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. The company reports 25,258 employees.

The most recent close on file for GRFS is $7.80, dated September 4, 2026. That is −$0.08 (−1.02%) against the previous close. Over the past 52 weeks the price has ranged from $6.96 to $10.23. The latest close sits 12.07% above that 52-week low.

Financial Health

In fiscal 2025, Grifols, S.A. reported revenue of $7.52B. That is +4.33% against the prior fiscal year, when revenue was $7.21B. The same year closed with net income of $402.00M. That is +156.05% against the prior fiscal year. The reported profit margin is 6.09%. That is 2 percentage points below the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to 0.76.

Across the 4 fiscal years on file, revenue moves from $6.06B in 2022 to $7.52B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 10.26 times earnings. That is 58.44% below the Drug Manufacturers - General median of 24.69. On forward earnings the ratio is 5.41. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.19. The price-to-sales ratio is 0.72. On price-to-sales that is 0.2 times the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Beta against the wider market is reported at 1.19. Annualized volatility over the trailing 10 years is 40.44%. Over the trailing twelve months the price has returned −20.15%. Across 10 years the annualized return works out at −5.65%.

Growth & Income

Shareholders receive a dividend, yielding 3.58% on the latest price. That is 0.9 percentage points above the Drug Manufacturers - General median yield of 2.7%. The indicated annual rate is $0.28 a share. The ex-dividend date on file is July 2, 2026. Dividends are recorded for 8 calendar years; 2026 shows 1 payments totalling $0.09 a share. The year before, 2025, totalled $0.17 a share.

2026 is still running; the price is −15.46% year to date. The strongest complete calendar year on file is 2017 at +45.07%; the weakest is 2021 at −37.47%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Grifols, S.A. (GRFS) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Grifols, S.A. GRFS $5.31B 10.3
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Grifols, S.A. trades at a P/E of 10.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Visit website →